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Abstract Cancer treatments, either chemo- or radiother-
apy, may cause severe damage to gonads which could lead
to the infertility of patients. In post-pubertal male patients,
semen cryopreservation is recommended to preserve the
potential to have their own biological children in the
future; however, it is not applicable to prepubertals. The
preservation of testis tissue which contains spermatogonial
stem cells (SSCs) but not sperm would be an alternative
measure. The tissues or SSCs have to be transplanted back
into patients to obtain sperm; however, this procedure
remains experimental, invasive, and is accompanied with
the potential risk of re-implantation of cancer cells.
Recently, we developed an organ culture system which
supports the spermatogenesis of mice up to sperm forma-
tion from SSCs. It was also shown that the tissues could be
frozen for later sperm production, which resulted in the
generation of offspring. Thus, it could be useful as a
clinical application for preserving the reproductive poten-
tial of male pediatric cancer patients. The establishment of
an optimized cryopreservation method and the develop-
ment of a culture system for human testis tissue are
expected in the future.
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Introduction
Owing to recent progress in medical treatments for cancer
patients, long-term survival and even cure have become
possible for young cancer patients. Therefore, an increas-
ing number of cancer survivors exist who are suffering
from the adverse effects of treatments they underwent.
Infertility is one of the side-effects and could be the most
influential factor affecting the psychological aspects of
their lives [1]. Thus, not only cancer treatment but also
fertility preservation has become important for cancer
patients, especially young people [2]. Our aim is to review
the up-to-date literature regarding the impact of cancer
treatment on male fertility and its prevention, including
semen cryopreservation. We also discuss experimental
challenges and our method of testis tissue cryopreservation
and in vitro spermatogenesis for preserving the fertility of
pre-adolescent male cancer patients.
Interest in fertility of male cancer survivors
A survey involving young cancer patients aged
14–40 years at the time of diagnosis showed that 51 % of
them wanted to have their own children in the future.
Moreover, this desire was naturally stronger in patients
who did not have children at the time of inquiry, with 77 %
of them answering in this way [3]. Another study demon-
strated that an even higher proportion of male patients
(70 %) wanted to have children in the future after finishing
the treatment [2]. Today, clinicians need to know the dis-
position of such patients, discuss the risk of infertility due
to the treatments, and present options for fertility preser-
vation prior to the treatments [4]. In 2006, the American
Society of Clinical Oncology (ASCO) recommended that
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clinicians include fertility preservation measures in the
cancer treatment scheme for each patient [5]. Such recog-
nition was not fully adopted among clinicians at that time.
A study showed that among 111 testis cancer survivors
aged 18-45 years at the time of diagnosis (from 2003 to
2007), 36 men (32 %) had not been informed about semen
cryopreservation before treatment [6]. A study in 2010
using a questionnaire survey involving 6,224 pediatric
cancer survivors revealed that they had significantly lower
chances of having children—56 % compared to their sib-
lings [7]. This does not directly reflect their reproductive
ability and may be associated with their lifestyle as a
cancer survivor as a whole, i.e., it emphasizes the impact of
the treatment that they underwent on their later lives.
Fertility after cancer treatment is now becoming a major
concern among young cancer patients and their families.
Gonadal toxicity of cancer therapy
In the mature testis, spermatogonia divide actively to
produce huge numbers of cells as the source of sperm.
Chemo- and radiotherapies preferentially impair dividing
cells, including spermatogonia and spermatocytes in the
testis. Human spermatogonia are classified into type A
(undifferentiated) and type B (differentiated). Type A
spermatogonia are further sub-classified into Adark and
Apale based on their nuclear features on hematoxylin
staining. Apale spermatogonia divide actively, while Adark
are relatively dormant and thought to be stem cells based
on studies in primates [8–10]. On the other hand, type B
spermatogonia divide more actively to differentiate into
spermatocytes. Thus, type B spermatogonia are more sen-
sitive to cytotoxic treatments than type A. It has been
reported, however, that even low doses of chemo- or
radiotherapy can induce apoptosis of not only type B but
also type A spermatogonia [11–14]. Naturally, treatment
with higher doses will destroy spermatogonia, leading to a
Sertoli-only state of the testis and inducing longer periods
of infertility in patients [15].
The effects of cytotoxic therapies can appear not only as
a reduction of sperm number, i.e., oligozoospermia or
azoospermia, but also as chromosomal aberrations of
sperm. The chromosome anomalies include aneuploidy,
partial defects, and translocation, which are triggered
mostly during the meiotic phase of spermatocytes. Thus,
their incidence rises rapidly after treatment and then
reportedly declines over time. The appearance of aneu-
ploidy, for example, was transient and reported to take
approximately 100 days to return to the pre-treatment level
[16]. Other reports, however, stated that aneuploidy
induced by cancer therapy lasted for 1–2 years or even
longer [17, 18], which indicates that spermatogonia along
with spermatocytes were influenced by cytotoxic
treatments.
Because alkylating agents, such as cyclophosphamide,
affect both dividing and dormant cells [19], they induce
marked spermatogenic impairment. A study which exam-
ined 355 male patients with Hodgkin’s lymphoma
12 months after treatment reported that follicle-stimulating
hormone (FSH), an increased level of which indicates
impaired spermatogenesis, was in the higher range in only
8 % of patients who were treated with regimens involving
non-alkylating agents alone, such as ABVD (doxorubicin,
bleomycin, vinblastine, and dacarbazine) or EBVP (epiru-
bicin, bleomycin, vinblastine, and prednisone). On the
other hand, high FSH was observed in 60 % of patients
treated with a regimen including alkylating agents, such as
MOPP (mechlorethamine, vincristine, procarbazine, and
prednisone), or MOPP/ABV (doxorubicin, bleomycin, and
vinblastine), or BEACOPP (bleomycin, etoposide, dox-
orubicin, cyclophosphamide, vincristine, procarbazine, and
prednisone) [20]. It was also reported that FSH recovered
to a normal range in 82 % of patients, taking a median of
19 months in cases treated without alkylating agents.
Meanwhile, it recovered in only 30 % of patients and took
a median of 27 months in cases treated with alkylating
agents [20]. Therefore, the adverse effect of alkylating
agents on spermatogenesis is severe and recovery takes a
long time or may not be achievable. The most effective
measure to mitigate their damage is naturally to avoid their
use by replacing them with other agents if possible. It is
also important to know the threshold doses of agents, if
available, whereby a higher does is likely to induce irre-
versible damage on spermatogenesis. For example, it has
been reported that cyclophosphamide with a total dose of
[7.5 g/m2 induced permanent infertility in approximately
90 % of patients, while doses\7.5 g/m2 allowed recovery
to a normospermic level in approximately 70 % of patients
[21].
Some agents other than alkylating ones are also toxic to
gonads. Among others, cisplatin, a platinum agent, is fre-
quently used for many cancers, including testicular cancer.
Analysis of 178 testicular cancer patients who underwent
chemotherapy using cisplatin identified 52 % patients
showing azoospermia 2 years after therapy, and 20 %
remained so at 5 years [22]. Again, the total cumulative
dose of cisplatin administered could be an indicator of
whether azoospermia is transient or permanent. When the
cumulative dose of cisplatin was\400 mg, being roughly
equivalent to 4 courses of state-of-the-art treatment, the
damage is likely to be reversible [23].
Radiation, similar to alkylating agents, markedly
impairs spermatogenesis. Total body irradiation, performed
as a conditioning measure for bone marrow transplantation
(BMT), significantly damages germ cells. After treatment
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with total body irradiation at a total dose of either 10 or
13 Gy, azoospermia was noted in 41 of 48 patients (85 %),
leaving the remaining 7 with oligozoospermia [24]. These
data signify the impact of irradiation on germ cells, con-
sidering that pre-treatment for BMT with cyclophos-
phamide alone rendered only 1 out of 10 patients with
azoospermia in the same study [24]. Regional irradiation as
well as total body irradiation could induce testicular
damage as some doses of radiation can be scattered outside
the targeted region. In the case of abdominopelvic irradi-
ation, approximately 1–2 % of doses aimed at the tumor
were estimated to reach the testes [25]. Damage of germ
cells directly induced by irradiation is proportional to the
dose. It was reported that doses as low as 0.1 Gy reaching
the testis resulted in the cessation of spermatogenesis [26].
A dose of 2–3 Gy causes long-term azoospermia, and
[6 Gy can deplete the spermatogonial stem cell pool and
lead to permanent infertility [26, 27].
In the testis, Leydig cells are also affected by radiation
when the dose is high enough [28]. A clinical study reported
the gonadal function of 15 boys with acute lymphoblastic
leukemia who had received testicular irradiation. Doses to
the testes were 12 Gy in 12 cases, 15 Gy in 1 case, and
24 Gy in 2 cases. All patients who received 12 or 15 Gy
showed normal Leydig cell function, but the 2 patients who
received 24 Gy suffered from depletion of testosterone and
required androgen replacement treatment [29].
Alleviation of radiation-induced damage to the testis
could be achieved only by minimizing the dose as low as
possible. This can be performed by shielding the testes or
reducing the radiation dose in the first place while main-
taining a sufficient effect. In the past, however, gonadal
protection through hormonal suppression was attempted,
based on the assumption that germ cells become less sen-
sitive to cytotoxic treatments when they are rendered to be
mitotically quiescent. In fact, this strategy was reported to
be effective in animal experiments using rats [30]; how-
ever, trials in clinical settings did not show the same results
[31–33]. A study reported that gonadotropin-releasing
hormone agonist treatment of seminoma patients who
underwent irradiation of their testes did not show protec-
tive effects when judged on serum levels of FSH,
luteinizing hormone, and testosterone [31].
Semen cryopreservation
As a means to preserve fertility, semen cryopreservation
prior to gonadal toxic therapy has been established for post-
pubertal patients. When micro-insemination was not avail-
able, cryopreserved sperm were used for artificial insemi-
nation. This was not successful in many cases because the
freezing and thawing procedure made the sperm less motile
and reduced their number. In addition, cryopreserved semen
would have been sufficient for only a single or a few
insemination procedures. Now that the intracytoplasmic
sperm injection (ICSI) procedure has been established and
become popular, cryopreserved sperm can be applied with
this technique. It was reported that the condition of sperm,
whether freshly obtained or cryopreserved, does not cause a
difference in the outcome, e.g., the pregnancy rate [34–36].
Thus, semen cryopreservation was validated as a method to
preserve the possibility of having one’s own biological child
in the future. Today, clinicians need be aware of it and are
requested to check if their patients are eligible for the pro-
cedure. Particularly in the case of patients in puberty, clini-
cians need to address if their patients have begun
spermatogenesis, and whether or not they can ejaculate. A
study reported that sperm in urinewere noted among 20 %of
11- to 12.5-year-old boys in Germany [37]. Other studies
reported that boys started masturbation at an average age of
12 years and 80 % of boys did so by the age of 13 years,
suggesting that boys aged C12 years in most cases can col-
lect semen by masturbation [38, 39]. Other studies reported
that all pubertal boys with testis volumes[10–12 mL are
encouraged to collect semen samples for preservation before
cancer therapy [39, 40].
Although semen collection is recommended prior to the
initiation of treatment, a study reported that 20 % of
patients had frozen their sperm during the course of cancer
treatment [41]. The fidelity of these sperm is at risk
because the cancer treatment would damage the DNA of
germ cells which could be carried up to sperm formation.
Thus, semen cryopreservation is definitely recommended
to be performed before treatment starts [41, 42].
Cryopreserved sperm has been used and resulted in the
birth of babies. One report stated that 29 patients who
preserved their semen underwent 87 cycles of reproductive
procedures in total, including 42 cycles of intrauterine
insemination (IUI), 26 of in vitro fertilization (IVF), and 19
of ICSI, resulting in a pregnancy rate of 18.3 % (7 % IUI,
23 % IVF, and 37 % ICSI) of which 75 % led to live births
(100 % IUI, 83 % IVF, and 57 % ICSI) [43]. Regarding
the preservation period, a case report proved the fertility of
sperm cryopreserved for 28 years by achieving a live birth
using micro-insemination [44]. Thus, sperm can be quite
resilient and cryopreservation secures them for several
decades.
As mentioned above, semen cryopreservation is a useful
and established method for post-pubertal patients to pre-
serve their reproductive potential. However, it is not
applicable for pre-pubertals. Therefore, cryopreservation of
SSCs or testis tissue en bloc would be an option. There are
various ways to obtain sperm from those samples, e.g.,
spermatogonial transplantation, testis tissue grafting, and
in vitro spermatogenesis.
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Spermatogonial stem cell transplantation
Spermatogonial transplantation was developed by Ralph L.
Brinster in 1994 [45]. It was also found soon after that cry-
opreservation of SSCs was possible and sperm production
from a frozen sample was performed by transplantation into
the seminiferous tubules of host mice [46]. The procedure of
spermatogonial transplantation was extensively studied in
mice and extended to rats as host animals [47]. Its application
was limited to rodents and interspecific transplantation was
also limited between species phylogenetically close to each
other, such as rats and mice or hamsters and mice [48, 49].
Recently, however, it was reported that the technique of
spermatogonial transplantation was modified and applied to
rhesusmacaques. In this case, the donor and host combination
was autologous or allogenic. The authors reported that the
injected SSCs differentiated up to sperm in the seminiferous
tubules in both autologous and allogeneic combinations [50].
Spermatogonial transplantation to the human testis was
investigated in the past. With the injection of a dye solution
into the seminiferous tubules of human testis, it was
reported that 55 % of the total tubular lumen was stained
[51]. Another study reported that ultrasound-guided injec-
tion was useful in the human testis [52]. Auto-transplan-
tation of the germ cells of 7 adult patients with Hodgkin’s
lymphoma was attempted in a study. The testicular cells of
patients were harvested and cryopreserved before treat-
ment, and were transplanted back into the seminiferous
tubules of each patient after treatment. The outcome of this
study, however, has not been reported [53, 54]. Although
these reports suggest that the injection of cells into human
seminiferous tubules is technically possible, the production
of sperm and harvesting them might not be sufficiently
feasible to be clinically applicable. One of the options
which could make spermatogonial transplantation more
generally applicable is to use purified SSCs. This could be
achieved if SSCs were cultured for propagation. Indeed, it
is possible in the case of mouse SSCs; however, the in vitro
propagation of human SSCs is not yet feasible.
Testis tissue grafting
Testicular grafting was found to be effective in inducing
spermatogenesis in a small piece of immature testis tissue
[55]. The main strength of this method is that it could be
applicable to diverse mammalian species, using nude mice
as a host animal [55, 56]. Pre-pubertal mouse, rabbit,
sheep, and pig testicular tissue surprisingly survived after
grafting in the dorsal subcutis of the host and produced
sperm, some of which had their fertility proven by micro-
insemination [57, 58]. A study reported that the grafting of
testis tissue from immature 13-month-old rhesus monkeys
into host mice resulted in the acceleration of testicular
maturation and production of fertility-competent sperm in
testis xenografts. Rhesus monkeys start spermatogenesis at
3–4 years old, but grafted testis tissues produced sperm in
7 months [59]. However, in the case of autologous grafting
of rhesus monkey testis tissues, a study reported different
results. One hundred and thirty pieces of cryopreserved
testis tissue derived from 5 rhesus monkeys, aged
30–49 months, in which spermatogenesis proceeded up to
preleptotene stermatocytes, were autologously grafted in
the subcutis of the scrotum, shoulder, back, and arms. At
5 months after implantation, sperm, round spermatids, and
pachytene spermatocytes were detected in 2 (1.5 %), 1
(0.8 %), and 4 (3.1 %) fragments, respectively. In addition,
the graft recovery rate was only 0–7 % [60]. Therefore, this
study concluded that in order to compensate for this low
recovery rate, the amount of testis tissue grafted should be
as much as possible, such as one whole testis.
To our knowledge, there has not been an autograft
experiment using human testis. There are, however, several
studies using immunodeficient mice as host animals [61,
62]. Testis tissue fragments measuring 0.5–1 mm3 from
32–40-year-old patients with obstructive azoospermia,
non-obstructive azoospermia, and testicular cancer were
grafted into nude or SCID mice. It was observed that most
seminiferous tubules underwent hyalinization changes
within a week and germ cells disappeared by 14 weeks
[61]. In another study using 4 mm3 testis tissue obtained
from patients who underwent reversal surgery for vasec-
tomy, 74 tissue pieces were grafted to the backs of SCID-
NOD mice. All grafts showed severe sclerotic change and
germ cells also disappeared in most cases, progressing only
up to the Sertoli cell-only state. Only 16 tissues (21.6 %)
maintained some spermatogonia [62]. On the other hand, a
study reported that xenografting of testicular tissue from an
infant human donor resulted in accelerated testicular mat-
uration [63]. Taken together, testis tissue grafting could be
a means to obtain sperm from immature testis tissues, but
its efficiency is not stable and may not be satisfactory. In
the case of adult tissue, the grafting cannot maintain
spermatogenesis, being rather prone to degeneration.
Cryopreservation technique of testis tissue
We report a possible new strategy to preserve fertility in pre-
pubertal male cancer patients. As we developed an organ
culture method which can support the complete spermato-
genesis of neonatal or pup mice, we applied this technique
and examined severalmethods of cryopreservation.Here, we
review cryopreservation and present our results.
Successful cryopreservation depends on the choice of
cryoprotectant and its concentration, and procedures both
24 Reprod Med Biol (2016) 15:21–28
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for freezing and thawing. In a study using a slow-freezing
procedure for pre-pubertal human testis tissues, dimethyl
sulfoxide (DMSO) was reported to be the most favorable
among the cryoprotectants tested, including ethylene gly-
col, propanediol, and glyceol, based on histological
observation regarding the maintenance of its architecture
along with the viability of constituent cells including
spermatogonia, Sertoli cells, and those in the interstitium
[64, 65]. In addition, the cryopreservation of immature
rhesus monkey testis tissues with DMSO showed the
resumption of spermatogenesis at xenografting [66]. These
reports along with others demonstrated the superiority of
DMSO as a cryoprotectant for testis tissue. It was recently
reported that DMSO added to sucrose appears to be a
choice of cryoprotectant for human testicular tissues, with
either a controlled or uncontrolled slow-freezing protocol
[67]. Some previous studies have used DMSO plus sucrose
for testis tissue cryopreservation, although its advantageous
effects were not clearly demonstrated [68–70].
There are some inconveniences regarding the slow-
freezing method in clinical settings because it generally
needs a programmable freezer and is time-consuming. In
this regard, the vitrification method is attractive. Vitrifi-
cation uses solution with a higher osmolality than those
used for slow freezing, and samples were placed immedi-
ately into liquid nitrogen, which makes the whole proce-
dure able to be completed in a short period. Vitrification
has been used for oocyte cryopreservation in clinics for
nearly a decade. Recently, its application to testis tissue or
spermatogonia was reported to be successful [67, 71, 72].
These studies showed the favorable maintenance of human
testis tissue, on the basis of histological observation, by the
vitrification method. At this moment, it remains unclear
which method (slow freezing or vitrification) is superior for
testicular tissue cryopreservation.
In vitro spermatogenesis of cryopreserved mouse
testis tissues
As stated above, spermatogonial transplantation and testis
tissue grafting could facilitate the production of sperm
from cryopreserved testis tissues. Both methods, however,
are accompanied by marked problems when considering
clinical application. Two serious problems in particular are
the invasiveness of the procedure, whether cell transplan-
tation or tissue grafting, to patients and, more seriously, the
cryopreserved samples might contain malignant cells of the
patient’s original disease. The transplantation or grafting of
such samples back into the body of each patient could lead
to the re-introduction of malignant cells. This risk seems to
be very small and negligible in most cases. Animal
experiments, however, demonstrated that as few as 20
leukemia cells were sufficient to cause a leukemic state in
rats after introduction into seminiferous tubules of the host
[73]. Cell-sorting methods, such as FACS, could be a
measure to prevent such re-inoculation of malignant cells,
but it is not reliable in reality [74, 75]. Xeno-transplanta-
tion or xeno-grafting would circumvent the re-introduction
of malignant cells, but they have their own problems and
concerns. One such concern is that a patient’s sperm pro-
duced in an animal’s body might carry substances of ani-
mal origin, viruses, or DNA fragments unique to the animal
[76].
Recently, our laboratory developed an organ culture
system for spermatogenesis and we succeeded in obtaining
functional sperm in neonatal mouse testis tissues in vitro
[77]. We then applied this culture method to cryopreserved
testis tissues. Spermatids and sperm were obtained in
samples cryopreserved by either slow-freezing or vitrifi-
cation methods; those haploids were used for microin-
semination using round spermatid injection and ICSI,
respectively, leading to offspring. They grew healthily and
produced the next generation by natural mating [78]. This
strategy, cryopreserving testis tissue followed by in vitro
spermatogenesis, overcomes the problems of the other
methods, i.e., the invasiveness of the procedure to patients,
and the risk of re-implantating cancer cells.
Conclusion
The infertility of male cancer survivors who have undergone
cytoablative therapies is a crucial problem. Physicians are
expected to provide patients with information about infertility
as one of the late-occurring adverse effects of treatment and on
preventive measures. For pre-adolescent male patients, we
expect testis cryopreservation and our culture system to
become a competent fertility-preservingmethod in the future;
however, our culture method is still only applicable to mouse
testis tissues. Thus, optimization of culture conditions for
human tissue is necessary. Further refinements of the cryop-
reservation technique are also required. Through these
improvements, this strategy may become a method to protect
and preserve the reproductive ability of youngmales, andmay
be applicable to pediatric cancer patients in the future.
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